US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose more than 4% after the UK approved the high-dose obesity treatment plan Wegovy 7.2 mg.

On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose more than 4%, closing at $59.49. According to reports, the UK drug regulatory agency has approved an increase in the maximum weekly dose of Wegovy, a popular weight-loss drug from Novo Nordisk A/S Sponsored ADR Class B, to 7.2 milligrams. Obese patients can inject this dose three times a week. This higher dose regimen was approved by the UK Medicines and Healthcare products Regulatory Agency on January 6, breaking the current limit of 2.4 milligrams and providing doctors and patients with a wider range of treatment options.